
    
      This is a single-center, open-label (identity of study drug will be known to participant and
      study staff), single-dose, parallel-group study. The study consist of Screening Phase (Days
      -21 to -2), Open-label treatment Phase (Day -1 up to Day 8) and End of Study (9 to 13 days
      after last study assessment). The total duration of study from the Screening Phase through
      Follow-up, is 37-41 days. Participants will be assigned to 1 of the two groups (Cohort 1 and
      Cohort 2) during the treatment phase. The participants will be primarily evaluated to
      determine the metabolic disposition of radiolabeled esketamine administered by the oral and
      intravenous routes. Participants' safety will be monitored throughout the study.
    
  